
the staff of the Ridgewood blog
Ridgewood NJ, Regeneron Pharmaceuticals on November 8 announced positive results from a Phase 3 clinical trial of its combination monoclonal antibody REGEN-COV for SARS-CoV-2 prevention. The trial—jointly run with the US National Institute of Allergy and Infectious Diseases (NIAID)—enrolled SARS-CoV-2-negative individuals who lived in the same household as someone who tested positive for SARS-CoV-2 within the prior 4 days. Participants received either one 1,200mg dose of REGEN-COV, administered via 4 subcutaneous injections, or a placebo.